Lonza
Lonza’s CEO Richard Ridinger is retiring from the company after seven years. As for his next steps, he intends to build a portfolio of non-executive positions in various companies.
Marc Funk next month will take over as the new CEO. He is currently the chief operating officer for the pharma and biotech division.
Ridinger will remain with the company until the end of April to ensure a smooth transition, and will be available in an advisory capacity until the end of 2019.
Ridinger said, “I am no less committed to the Board of Directors for the trust placed in me and for our constructive cooperation … Lonza is in a very strong position, and I will be working closely with Marc over the coming months to ensure a smooth transition and the continuation of the company’s success.”
As the incoming CEO, Funk said he is committed to building on the company’s foundation and to “driving forward the strategy across all our businesses along the health care continuum.”